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Abstract
Background: Left atrial (LA) enlargement and dysfunction are related to clinical course in patients with hypertrophic
cardiomyopathy (HCM). We aimed to investigate genetic contribution to LA structural and functional remodeling.
Methods: Two hundred twelve patients were consecutively enrolled, and echocardiography and extensive genetic
analysis were performed. Cardiac magnetic resonance (CMR) was performed in 135 patients. Echocardiography was
also performed in controls (n = 30).
Results: Patients with HCM had lower late-diastolic mitral annular velocity (a’) and higher LA volume index (LAVI)
than controls. Patients with pathogenic or likely pathogenic sarcomere gene mutations (PSM, n = 67, 32%) had
higher LAVI and lower CMR-derived LA total emptying fraction (37.0 ± 18.5 vs. 44.2 ± 12.4%, p = 0.025). In patients
without AF (n = 187), the PSM had lower a’ (6.9 ± 2.0 vs. 7.8 ± 1.9 cm/s, p = 0.004) than others. The PSM had
higher prevalence and amount of late gadolinium enhancement (LGE) in the left ventricle (LV). In multivariate
analysis, PSM was significantly related to lower a’ independent of E/e’, LV mass index, and LAVI. However, the
relation significantly attenuated after adjustment for the extent of LGE in the LV, suggesting common myopathy
in the LV and LA. In addition, PSM was significantly related to lower LA total emptying fraction independent of
age, E/e’, s’, LV ejection fraction, LV myocardial global longitudinal strain and %LGE mass.
Conclusions: PSM was related to LA dysfunction independent of LV filling pressure and LAVI, suggesting its
contribution to atrial myopathy in HCM.
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Background
Left atrial (LA) enlargement and dysfunction are related
to the development of atrial fibrillation (AF) and exercise
intolerance in patients with hypertrophic cardiomyop-
athy (HCM) [1–3]. LA dysfunction is usually related to
chronic structural remodeling owing to long-standing
pressure and volume overload. In addition, LA structural
remodeling such as enlargement or fibrosis is a marker
of development of AF in HCM [4]. Recent studies also
showed that LA function measured by strain imaging is
an independent predictor of poor outcome in patients
with HCM [1, 2]. However, it has been reported that in
HCM, LA dysfunction can occur as a myopathic process
itself, irrespective of loading conditions [4, 5]. In this re-
gard, genetic contribution to LA structural and func-
tional remodeling has not been well investigated. Tissue
Doppler imaging-based late mitral annular velocity (a’)
and LA phasic function have been validated as good LA
functional parameters reflecting active contraction in
several studies and are widely used [6]. Herein, we
sought to evaluate the relationship between related gene
mutations and LA function in patients with HCM. In
addition, we aimed to study the direct effect on LA func-




A total of 432 patients treated at a single center were en-
rolled in an HCM Registry from 2006 to 2014. Among
them, 220 patients were excluded owing to insufficient
data, follow-up loss, or declining study enrollment. Fi-
nally, 212 patients underwent genetic testing. The pa-
tients had maximal left ventricular (LV) hypertrophy
greater than 13 mm and a ratio of maximal thickness to
posterior wall thickness greater than 1.3 without an
underlying cause of hypertrophy, such as uncontrolled
hypertension or aortic stenosis. Patterns of LV hyper-
trophy were classified as ApHCM and non-ApHCM
(asymmetrical hypertrophy, diffuse hypertrophy, and
focal segmental hypertrophy). All patients underwent
screening for Fabry disease and were confirmed negative
for the galactosidase alpha variant. For comparison, con-
ventional echocardiography was performed in controls.
The study protocol conformed to the ethical guidelines
of the 1975 Declaration of Helsinki, and it was approved
by institutional review board of Gangnam Severance
Hospital (3–2015-0019). Written informed consent was
obtained from all participants.
Genetic testing and analysis
HCM gene panel (nDNA) and mtDNA design
HCM genes consisted of 8 validated sarcomere genes
and 25 putative HCM genes [7]. A comprehensive
HCM-specific panel, consisting of 82 nuclear DNAs
(nDNAs: 33 sarcomere-associated genes, 5 phenocopy
genes, and 44 nuclear genes linked to mitochondrial car-
diomyopathy) and 37 mitochondrial DNAs (mtDNAs),
was analyzed (Supplementary Table S1).
DNA preparation, library construction and sequencing of
HCM gene panel and mtDNA
The details are described in Supplementary Method 1 to
3.
Identification of potential pathogenic mtDNA variants
Mitochondrial genome databases, including MITOMAP
[8] and Human Mitochondrial Genome Database
(mtDB) [9] and Phylotree [10] were referred to validate
the detected variants. Novel and rare non-haplogroup-
associated variants were further evaluated for their po-
tential pathogenicity based on the variant’s location,
changes in the amino acid sequence, and evolutionary
conservation [11]. We have assessed potential pathogen-
icity using multiple software programs including Poly-
phen2, Fathmmw, Mutation Assessor, and PROVEAN.
When the majority of computational evidence supported
a deleterious effect, we have assigned novel and rare
non-haplogroup-associated variants as damaging
mtDNA variants [12]. Data analysis of mitochondrial
genome are described in Supplementary Method 4.
Data analysis of the HCM gene panel
The Burrows–Wheeler aligner algorithm with default
parameters was used to align reads to the human refer-
ence genome sequence GRCh37 [13]. SAMTools was
used to convert the sequence alignment map file to the
BAM format [14]. Duplicates were sorted and removed
using the Picard tool (http://broadinstitute.github.io/
picard/). The Genome Analysis Toolkit was used for
indel realigning and base-quality score re-calibration
[15]. Variants were further filtered with altered allele fre-
quency > 30%, 50× coverage. For 33 HCM genes,
annotated variants using ANNOVAR [16] and Variant
Effect Predictor (http://asia.ensembl.org/info/docs/tools/
vep/index.html) were classified as pathogenic and likely
pathogenic based on refined American College of Med-
ical Genetics and Genomics (ACMG) standards and
guidelines for inherited cardiac conditions [12, 17–19].
For 44 mitochondria-related nuclear DNA genes (reces-
sive conditions), annotated variants were classified as
pathogenic and likely pathogenic based on ACMG
guidelines [17]. And we adapted gnomAD AF cutoff
0.01% as the moderate level of evidence supporting
pathogenicity (ACMG/AMP criterion PM2) based on
maximum credible population AF (http://cardiodb.org/
allelefrequencyapp/) [17, 18].
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Echocardiographic analysis
Comprehensive echo-Doppler evaluation was performed
according to the current American Society of Echocardi-
ography guidelines [20]. LV ejection fraction was mea-
sured by biplane Simpson’s method. LA volume was
measured at the end-systole by the ellipsoidal method,
and LA volume index was calculated as LA volume/body
surface area (BSA). Peak early (E) and late (A) diastolic
mitral inflow velocities were measured in apical four-
chamber view. The filter was set to exclude high fre-
quency signal, and the Nyquist limit was adjusted to a
range of 15 to 20 cm/s. Gain and sample volume were
minimized to allow for a clear tissue signal with minimal
background noise. Systolic (s’), early (e’) and late (a’) dia-
stolic velocities of the mitral annulus were measured
from the apical 4-chamber view with a 2- to 5-mm sam-
ple volume placed at the septal corner of the mitral an-
nulus. (Fig. 1) The ratio of E/e′ was calculated. LV wall
thickness was measured in all cross-sectional planes.
Continuous wave Doppler was used to measure the peak
velocity across the LV outflow tract (LVOT), and the
pressure gradient was calculated using the Bernoulli
equation, as follows: 4 × (peak velocity across the
LVOT)2 [21]. It was measured at rest and during Val-
salva maneuver. LVOT obstruction was defined as a sys-
tolic pressure gradient ≥30mmHg.
Cardiac magnetic resonance imaging (CMR) and LV
chamber performance assessment
CMR was performed using a 1.5-T scanner (Magnetom
Avanto®; Siemens Medical Solutions, Erlangen, Germany)
with a phased array body coil. (Supplementary Method 5).
Extent of LGE assessment
From the LGE images, the LV was divided into 16 seg-
ments [22]. Presence of LGE involvement in each seg-
ment and the total number of LGE-involving segments
were measured. In addition, the percentage of LGE in
LV mass were measured using dedicated quantitative
analysis software (Qmass®MR 8.1, Medis, Leiden,
Netherland) using LGE images with PSIR sequence. To
improve the reproducibility, experienced radiologist and
cardiologist with more than 10 years of experience ana-
lyzed the LGE sizes. In each short-axis slice image, the
Fig. 1 Tissue Doppler index (right panel) and phasic left atrial function measurement with cardiac magnetic resonance imaging (right panel) in a
patient with pathogenic sarcomere gene mutation (TNNI3 mutation, a, b) and without sarcomere mutations (c, d)
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boundaries of contrast-enhanced areas were automatic-
ally traced. On LGE-MR images, myocardium with ab-
normal enhancement was defined as an area of hyper-
enhancement more than five standard deviations from
the remote myocardium. Remote myocardium was de-
fined as non-enhanced myocardium, opposite of the
hyper-enhanced myocardium [23]. The maximum signal
was determined by computer-assisted window threshold-
ing of the enhanced area. Obvious artifacts, such as
those caused by motion, were excluded using a tool from
the software package. Total LGE amount was calculated
by summation of all slice volumes of enhancement.
Myocardial strain analysis using feature tracking CMR
Myocardial strain analysis using feature tracking CMR
was performed in 135 patients with semi-automated
software (Qstrain®MR 2.0, Medis, Leiden, Netherland).
LV endocardial borders were manually drawn at a ref-
erence frame. LV endocardial and epicardial borders
were manually traced in 2-, 3-, 4-chamber long-axis
views at end-systolic and end-diastolic phase. LV glo-
bal longitudinal strain (GLS) was obtained from aver-
aging longitudinal strains of apical 2-, 3-, and 4-
chamber view. LA endocardial border was manually
traced in 4-chamber long-axis view using LV end-
diastole as reference phase. LA global longitudinal
strain is defined as the average peak strain value. LA
maximal, pre-contraction (pre-A in cases without AF)
and minimal volume were measured [24]. LA total
emptying fraction was calculated as (LA maximal vol-
ume – LA minimal volume) / LA maximal volume.
LA reservoir fraction, as (LA maximal volume – LA
minimal volume / LA minimal volume), LA conduit
fraction as (LA maximal volume – LA pre-A volume)
/ LA maximal volume, and LA active emptying frac-
tion as (LA pre-A volume – LA minimal volume) /
LA pre-A volume [6]. (Fig. 1).
Statistical analysis
Continuous variables with normal distributions are re-
ported as the mean ± standard deviation or 95% confi-
dence interval. Student’s t-tests were used to compare
the means of continuous variables that were approxi-
mately normally distributed between the two groups.
Normality was determined using the Shapiro–Wilk
test. Categorical variables are reported as counts (or
percentages) and were compared using chi-square
tests. For comparison of more than two groups, ana-
lysis of variance was performed with post-hoc analysis
(LSD) for subgroup comparison. For the correlates of
LA function, Pearson’s correlation coefficients were
determined and Pearson’s correlation analyses were
performed. For the multivariable analysis, linear re-
gression analysis or logistic regression analysis was
performed with variables with p < 0.05 in univariate
analysis to check the independence of the variables.
All statistical analyses were performed using SPSS
version 25.0 (IBM Corp., Armonk, NY, USA). A two-




The mean age of the patients was 59 ± 14 years, and 63
(30%) of them were female. Of the total patients, 49
(23%) had obstructive HCM; 100 patients (47%) had
ApHCM, and 64 (64%, 64/100) of these had pure-type
ApHCM. Patients with HCM had higher LA volume
index and lower a’ than those of age- and sex- matched
controls. CMR was performed in 135 patients (LGE in
133 patients). The mean LV mass index was 85.7 ± 22.9
g/m2; 92 (69%) patients showed evidence of LGE. The
average number of LGE segments and %LGE mass were
3.5 ± 3.4 and 8.0 ± 9.7%, respectively (Table 1).
Genetic characteristics
Based on the American College of Medical Genetics
and Genomics guidelines, [19] 67 of 212 (32%) pa-
tients had 71 pathogenic or likely pathogenic variants
in 33 sarcomere-associated genes (33 MYBPC3, 19
MYH7, 14 TNNI3, 2 MYH6, 1 JPH2, 1 TNNC1, and 1
MYL3). Four patients harbored more than one vari-
ants in HCM genes. Homozygous or compound het-
erozygous variants in MYBPC3 were identified in one
patient and co-variants were identified in three pa-
tients (two had MYBPC3 and MYH7, and one had
MYBPC3 and JPH2). In total, 26 (12%) patients had
probably damaging mtDNA variants (one patient was
missed due to non-analysis of mtDNA), 15 (7%) had
mitochondria-related nDNA variants, and 1 had a
pathogenic variant in GAA. Seven patients (3%) had
both pathogenic sarcomere gene variants and
mitochondria-related variants. Detailed genetic vari-
ants of detected sarcomere genes, mitochondria-
related nDNAs and damaging mtDNAs are shown in
Supplementary Table S2, S3 and S4 [12]. The patients
with pathogenic or likely pathogenic sarcomere gene
mutations (PSM) had higher prevalence of LGE (90%
vs. 63% vs. 50%, p = 0.001) and number of LGE-
involved segments (4.9 ± 2.8 vs. 2.9 ± 3.3 vs. 2.6 ± 3.8,
p = 0.005) than patients without any mutations and
those with mitochondria-related mutations.
Effects of sarcomere mutations on LA function
The PSM (n = 67, 32%) had higher LA volume index
(41.0 ± 22.0 vs. 34.9 ± 15.0 mL/m2, p = 0.045) and ten-
dency of higher prevalence of AF (16.4% vs. 9.7%, p =
0.156). Even in patients without AF (n = 187), PSM had
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Table 1 Clinical, echocardiographic, electrocardiographic, and cardiac magnetic resonance imaging findings in controls and patients
with hypertrophic cardiomyopathy according to sarcomere gene mutations
Control
(n = 30)
HCM (n = 212)
Presence of sarcomere protein gene variant
group (n = 67)
Absence of sarcomere protein gene variant group
(n = 145)
‡p
Age, years 58.9 ±
2.6
54.8 ± 14.3 61.3 ± 12.8 0.001
Women, n (%) 10 (33) 25 (37) 38 (26) 0.106
Hypertension, n (%) 11 (37)* 28 (42) 91 (63) 0.004
Diabetes, n (%) 5 (17) 12 (18) 27 (19) 0.884
Persistent AF at echo, n (%) 11 (16) 14 (10) 0.156
NSVT at 24-h Holter, n (%) (n = 123) 10 (22) 7 (9) 0.049
5-year SCD risk, % (n = 123) 2.64 ± 1.51 2.01 ± 1.66 0.040
Echocardiography
ApHCM, n (%) 21 (31) 79 (55) 0.001
Dynamic obstruction, n (%) 13 (19) 36 (25) 0.370
LV ejection fraction, % 65.7 ±
3.8
63.8 ± 7.3 64.9 ± 5.8 0.239
LA volume index, mL/m2 19.8 ±
3.4†
41.0 ± 22.0 34.9 ± 15.0 0.045
e’, cm/s 6.9 ± 1.5† 5.1 ± 1.8 5.1 ± 1.7 0.960
a’, cm/s 10.3 ±
1.7†
6.9 ± 2.0 7.8 ± 1.9 0.004
s′, cm/s 8.8 ± 1.6† 6.6 ± 1.6 6.8 ± 1.8 0.408
E, cm/s 64.5 ±
14.1
71.0 ± 23.2 68.7 ± 18.0 0.463
A, cm/s 75.7 ±
15.9
61.9 ± 19.6 72.4 ± 20.8 0.001
E/e′ 9.8 ± 2.8† 15.4 ± 6.7 14.6 ± 5.5 0.371
Maximal thickness, mm 19.7 ± 3.7 18.6 ± 3.4 0.035
CMR (n = 135)
LVEDV, mL 133.6 ± 28.6 135.7 ± 28.2 0.698
LVESV, mL 51.7 ± 23.1 46.9 ± 18.5 0.208
LV mass index, g/m2 88.0 ± 21.1 84.8 ± 23.8 0.456
LV mass/volume ratio 1.19 ± 0.32 1.14 ± 0.32 0.469
Presence of LGE in LV (n = 133) 37 (90) 55 (60) <
0.001
Number of LGE segments in
LV(n = 133)
4.9 ± 2.8 2.9 ± 3.5 0.002
% LGE amount of LV(n = 133) 10.6 ± 10.1 6.4 ± 9.3 0.040
LV myocardial GLS, % −14.6 ± 5.7 −16.2 ± 4.0 0.100
LV endocardial GLS, % −17.5 ± 5.5 −20.6 ± 4.2 0.058
LA minimal volume index, mL/m2 49.0 ± 35.9 37.3 ± 20.4 0.053
LA GLS, % 17.7 ± 11.5 19.8 ± 9.1 0.288
LA total emptying fraction, % 37.0 ± 18.5 44.2 ± 12.4 0.025
LA reserve fraction, % 73.1 ± 52.1 89.3 ± 50.8 0.090
LA conduit fraction, % (n = 119) 20.0 ± 11.7 21.8 ± 8.3 0.433
LA active emptying fraction, %
(n = 119)
27.0 ± 14.8 31.3 ± 11.3 0.093
*p < 0.05; †p < 0.01, compared with total patients with hypertrophic cardiomyopathy; ‡p, comparisons between patients with and without sarcomere gene
mutations; HCM hypertrophic cardiomyopathy; ApHCM apical HCM; AF atrial fibrillation; NSVT non-sustained ventricular tachycardia; SCD sudden cardiac death; LV
left ventricle; LVEDV LV end-diastolic volume; LVESV LV end-systolic volume; LVEF LV ejection fraction; LA left atrial; e’ early diastolic mitral annular velocity; a’ late
diastolic mitral annular velocity; s’, systolic mitral annular tissue velocity; E early diastolic transmitral inflow velocity; A late diastolic transmitral inflow velocity; LGE
late gadolinium enhancement, GLS global longitudinal strain
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significantly lower A (61.9 ± 19.6 vs. 72.4 ± 20.8 cm/s,
p = 0.001) and a’ (6.9 ± 2.0 vs. 7.8 ± 1.9 cm/s, p = 0.004).
PSM had lower LA total emptying fraction by CMR than
others (44.2 ± 12.4 vs. 37.0 ± 18.5%, p = 0.025). However,
patients with only mitochondria-related mutations had
higher a’, compared with PSM (8.6 ± 3.3 vs. 6.9 ± 2.0 cm/
s, p < 0.001) (Fig. 2). Within PSM, those with TNNI3
mutation and MYH6 had lower a’, A and higher LA vol-
ume index than others (Fig. 3). Patients with thick fila-
ment mutations (n = 46) had a lower A (64.0 ± 19.0 vs.
71.0 ± 21.2 cm/s, p = 0.048) and a tendency to lower a’
(7.13 ± 1.96 vs. 7.68 ± 1.96 cm/s, p = 0.099) compared
with those without thick filament mutations (n = 141).
Correlates and independent relationship of sarcomere
mutations to LA function
Patients with ApHCM had higher a’ than that of patients
without ApHCM. In univariate analysis, a’ was signifi-
cantly correlated to LA volume index, E/e’, e’, and s’. In
addition, LV mass index, LA minimal volume, LA total
emptying fraction, LA active emptying fraction, 5-year
Fig. 2 Comparison of prevalence of atrial fibrillation (a), left atrial volume index (b), and a’ velocity (c) and left atrial total emptying fraction (d)
between sarcomere gene mutation-positive group and mutation-negative group. Comparison of left atrial volume index (e), and a’ (f) velocity
between sarcomere- and mitochondria-related gene mutation groups*. HCM, hypertrophic cardiomyopathy; AF, atrial fibrillation, LA, left atrial, TDI,
tissue Doppler imaging; a’, peak late-diastolic septal mitral annular; CMR, cardiac magnetic resonance imaging; bar indicates standard error; *one
patient was missed due to non-analysis of mtDNA
Chung et al. Cardiovascular Ultrasound            (2021) 19:4 Page 6 of 11
risk of sudden cardiac death, and the presence and num-
ber of LGE segments were significantly correlated to a’
but not with LV global longitudinal strain. In multivari-
ate analysis, PSM was significantly related to a’ inde-
pendent of the presence of ApHCM, E/e’, s’, and LA
volume index. When using the definition of a’ < 6 cm/s
(less than 3rd quartile value) as LA dysfunction, PSM
was also significantly correlated to LA dysfunction inde-
pendent of ApHCM, E/e’, s’ and LA volume index by
echocardiography (Table 2). However, the relation sig-
nificantly attenuated (p > 0.05) after adjustment for the
presence of LGE or number of LGE segment in LV,
which suggests common myopathy in LV and LA. In
subgroup who underwent CMR, LA total emptying frac-
tion was significantly correlated to age, E/e’, s’, a’, %LGE
mass, LV ejection fraction by CMR, LV myocardial GLS
and presence of sarcomere mutations. In multivariate
analysis, presence of sarcomere mutations was signifi-
cantly correlated to LA total emptying fraction inde-
pendent of age, E/e’, s’, LV ejection fraction by CMR, LV
myocardial GLS and %LGE mass (Table 3).
Discussion
This study shows the following major findings. First, LA
function was significantly reduced in patients with
HCM, compared with controls despite same age and sex
distribution. Second, among patients with HCM, the
PSM had significantly reduced LA function (measured
by a’ in echo and LA total emptying fraction by CMR),
compared with patients without sarcomere gene muta-
tions. Third, worse LA function in the PSM was inde-
pendent of the LA volume index, LV mass index, and E/
e’. Fourth, LA function, measured by a’, was significantly
correlated to the extent of LGE in LV, and the PSM had
significantly higher extent of LGE. Although, the rela-
tionship between sarcomere gene mutation and a’ was
significantly attenuated after adjustment for the extent
of LGE in LV, the LA total emptying fraction was signifi-
cantly correlated to sarcomere gene mutation independ-
ent of %LGE mass, which suggests that LA dysfunction
is a unique finding of HCM as an LA myopathy related
to sarcomere gene mutations independent of LA loading
conditions. Although we did not measure LA fibrosis by
LGE quantification, this finding suggests that sarcomere
gene mutation may contribute to both LV and LA my-
opathy, and may then induce LA dysfunction. This
sarcomere gene mutation- related LA dysfunction is not
just through elevated LV filling pressure, because even
after adjustment for E/e’, LA volume index, and LV mass
index, sarcomere gene mutation-related LA dysfunction
remained significant. In addition, the findings that PSM
were significantly younger than those in the non-
sarcomere-related group and the LA function of patients
with HCM was significantly lower than controls despite
same age and sex distribution, suggest that LA dysfunc-
tion in HCM is a unique myopathic process and that
sarcomere gene mutation significantly contribute to LA
dysfunction. Previous basic studies showed that sarco-
mere gene mutation directly induces myocyte hyper-
trophy, myocyte disarray, and fibrosis in the LV in HCM
mouse models [25]. Some studies showed that TGF β1-
medicated LA fibrosis also developed in sarcomere gene
mutation-derived mouse HCM models only with dys-
functional LV [25], which supports our speculation of a
common myopathic process in the LV and LA. This
finding also suggests that current anti-hypertrophy and
anti-fibrotic agents [26] would affect LA structural and
functional remodeling, thereby reducing AF. In our
study, mitochondria-related mutations were not signifi-
cantly related to LA dysfunction and LV fibrosis; there-
fore, phenotypic contribution and myocardial fibrosis is
mainly contributed by pathogenic sarcomere gene muta-
tions. Despite the small number of subjects with
validated pathogenic sarcomere gene mutations in our
study, the degree of genetic contribution to LA function
seemed to vary between mutations. According to our
study, patients with TNNI3 mutation had worse LA
function than patients with MYBPC3 mutation did,
whereas mitochondria-related gene mutations showed
more benign phenotypes in terms of LA function.
Therefore, gene-targeted therapy needs to be
individualized.
Prevention of sudden cardiac death due to ventricular
tachycardia is a major goal of management of HCM
Fig. 3 Comparisons of a’ (a), A (b) velocity and left atrial volume index (c) within patients with individual sarcomere gene mutations
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[27]. However, several recent studies showed that the
general prognosis of HCM is better than that in previous
reports, and active primary prevention has reduced the
rate of sudden deaths related to HCM [28]. With the ad-
vancing age of patients with HCM, heart failure due to
advanced diastolic dysfunction or development of AF be-
come a major concern [29]. In fact, several studies
showed that concomitant or newly developed AF is a
major prognostic factor for heart failure admission, new-
onset stroke, and mortality in HCM [30, 31]. Therefore,
prevention of AF should be one of the goals of manage-
ment of HCM. In this regard, several new attempts for
upstream genetic modulation using CRISPR/Cas9, [32] a
sarcomere-targeted anti-hypertrophic or anti-fibrotic
agent, [26] could have potential preventive effects on the
development of AF and heart failure.
This study has several limitations. First, we did not
evaluate the myopathic process of the LA itself, such as
direct tissue characterization or CMR-derived LA fibrosis
measurement [33]. However, measurement of LA-LGE
involves extensive variability, and 3D-LGE is not routinely
measured in most institutions. Hence, use of the most
popular parameters with less measurement variability
would be justified. Further studies are warranted to de-
velop a more accurate and reproducible method for asses-
sing the LA myopathic process in HCM. Second, owing to
lack of long-term follow-up data, the relationship between
LA dysfunction and future development of new-onset AF
or heart failure was not proved. However, several previous
studies showed that LA structural or functional remodel-
ing was significantly related to poor outcomes, especially
to the development of new-onset AF and heart failure [1,
2]. The findings of this study could help elucidate this re-
lationship. In addition, our results attempt to explain the
reason behind the worse prognosis of PSM among those
with HCM. Third, due to limited number of CMR, LA ac-
tive emptying fraction did not reach the statistical differ-
ences between sarcomere groups. However, LA total
emptying fraction was significantly lower in sarcomere
mutation groups even in the limited patients, which
Table 2 Univariate and multivariate analysis for a’ velocity
a’ LA dysfunction (a’ < 6 cm/s)
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
(r) (p) (β) (p) OR (95% CI) p OR (95% CI) p
Age, per year 0.102 0.166 0.98 (0.95–1.01) 0.098
Dynamic obstruction −0.069 0.348 3.68 (1.60–8.45) 0.002
ApHCM 0.182 0.013 0.057 0.341 0.38 (0.16–0.90) 0.029 1.34 (0.39–4.57) 0.638
LVEF-by echo, per % 0.030 0.683 0.93 (0.88–0.99) 0.015
E, per cm/s −0.260 < 0.001 26.39 (3.40–204.94) 0.002
A, per cm/s 0.291 < 0.001 0.06 (0.006–0.49) 0.009
e’, per 100 cm/s 0.232 0.001 0.74 (0.57–0.97) 0.030
E/e’ 0.411 < 0.001 −0.089 0.190 1.17 (1.08–1.25) < 0.001 1.07 (0.97–1.17) 0.182
s’, per 100 cm/s 0.592 < 0.001 0.484 < 0.001 0.47 (0.34–0.65) < 0.001 0.52 (0.34–0.78) 0.001
LA volume index, per mL/m2 −0.418 < 0.001 − 0.200 0.002 1.05 (1.03–1.07) < 0.001 1.04 (1.01–1.07) 0.004
Presence of sarcomere mutations 0.211 0.004 −0.138 0.017 4.76 (2.05–11.02) < 0.001 5.33 (1.71–16.61) 0.004
LV mass index by CMR (n = 135) −0.214 0.021 1.02 (1.00–1.05) 0.046
Presence of LGE (n = 133) −0.248 0.007 1.89 (0.49–7.21) 0.353
No of LGE segment (n = 133) −0.334 < 0.001 1.26 (1.07–1.49) 0.006
%LGE mass (n = 133) −0.132 0.156 1.03 (0.97–1.09) 0.312
LV myocardial GLS (n = 135) −0.045 0.627 1.05 (0.93–1.18) 0.435
LA GLS (n = 135), per % 0.076 0.413 0.92 (0.85–0.99) 0.034
LA minimal volume (n = 135), per mL −0.443 < 0.001 1.03 (1.02–1.05) < 0.001
LA maximal volume (n = 135), per mL −0.427 < 0.001 1.02 (1.01–1.04) 0.001
LA total emptying fraction (n = 135), per % 0.251 0.006 0.93 (0.89–0.97) 0.001
LA active emptying fraction (n = 119), per % 0.248 0.006 0.93 (0.88–0.97) 0.003
5-yr-SCD risk (n = 123) −0.314 0.001 1.45 (1.06–1.99) 0.020
Presence of NSVT (n = 123) −0.214 0.036 5.27 (1.58–17.66) 0.007
Abbreviations are same as in Table 1
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supports our observation measured by a’ velocity. Larger
number of echocardiographic or CMR studies with phasic
LA functional analyses warrant further investigation.
Conclusion
Presence of pathogenic sarcomere mutation was signifi-
cantly related to LA dysfunction independent of LV fill-
ing pressure and LAVI, suggesting its contribution to
atrial myopathy in HCM. Therefore, our study results
may provide an explanation why HCM patients with
sarcomere gene mutations had poorer prognosis, regard-
ing higher prevalence of AF and hospitalization due to
heart failure [34].
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